Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their target price on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.

Minerva Neurosciences Stock Up 0.8 %

Shares of NERV stock opened at $2.46 on Friday. The firm has a market capitalization of $17.20 million, a price-to-earnings ratio of -0.55 and a beta of 0.14. Minerva Neurosciences has a 12-month low of $2.26 and a 12-month high of $13.49. The firm has a fifty day moving average of $2.68 and a 200-day moving average of $2.80.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Research analysts expect that Minerva Neurosciences will post -2.26 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.